Hidradenitis suppurativa: vizsgálatok itt: Kína

In Kína 13 Also abroad 72

13 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.

3. fázisTaking people
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Where
Beijing
Életkor
18 év to 100 év
People
710 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07665437 · EU 2025-523259-72-00
2. fázisTaking people
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Where
Beijing, Changsha, Hangzhou, Shanghai, Wuhan
Életkor
18 év and over
People
144 worldwide
Run by
Sanofi
See details and how to joinNCT07225569 · EU 2025-522695-83-00
2. fázisTaking people
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Where
Chengdu, Guangzhou, Shanghai, Ürümqi
Életkor
18 év and over
People
208 worldwide
Run by
Sanofi
See details and how to joinNCT07170917 · EU 2025-522333-61-00
4. fázisTaking people
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wenzhou
Életkor
18 év and over
People
36
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07489573
1/2. fázisTaking people
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
Where
Beijing
Életkor
18 év to 75 év
People
12
Run by
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
See details and how to joinNCT06932003
No phaseTaking people
Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRI
Where
Changsha
Életkor
18 év to 45 év
People
80
Run by
Second Xiangya Hospital of Central South University
See details and how to joinNCT07755670
4. fázisNot yet taking people in Kína
A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa
Where
Hangzhou
Életkor
18 év and over
People
50
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07554014
1/2. fázisTaking people
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
Where
Jinan
Életkor
18 év and over
People
15
Run by
Shanghai Huaota Biopharmaceutical Co., Ltd.
See details and how to joinNCT06895499
4. fázisNot yet taking people in Kína
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Where
Nanjing
Életkor
18 év and over
People
30
Run by
Peking Union Medical College
See details and how to joinNCT07261072
No phaseTaking people
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
Where
Beijing
Életkor
18 év and over
People
50
Run by
Peking Union Medical College
See details and how to joinNCT07109765
1. fázisTaking people
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
Where
Beijing
Életkor
18 év to 75 év
People
102
Run by
Shanghai Qilu Pharmaceutical Research and Development Center LTD
See details and how to joinNCT06946641
No phaseTaking people
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
Where
Nanjing
Életkor
Up to 80 év
People
100
Run by
Peking Union Medical College
See details and how to joinNCT06926192
No phaseTaking people
A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients
Where
Hangzhou
Életkor
18 év to 75 év
People
60
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06707246